CagriSema REDEFINE-1 results explained vs the next-gen GLP-1 family

What CagriSema is, in one paragraph

CagriSema is the working name for a once-weekly combination of two peptide drugs in one pen: cagrilintide, a long-acting analog of the gut hormone amylin, plus semaglutide, the GLP-1 receptor agonist marketed as Wegovy and Ozempic. The combo targets two different fullness pathways at once -- amylin in the brainstem and GLP-1 across the gut and brain -- to deliver more weight loss than either drug alone. It is investigational, not yet FDA-approved.

Cagrilintide is an investigational peptide from Novo Nordisk that imitates amylin, a hormone your pancreas releases alongside insulin when you eat to signal fullness. semaglutide is the GLP-1 (glucagon-like peptide-1, a gut hormone that lowers appetite and slows digestion) agonist marketed as Wegovy and Ozempic. CagriSema combines both in one once-weekly injection. the bet: two different fullness signals beat one. the phase 3 trials tested that.

The peer-reviewed papers for the two pivotal trials, REDEFINE-1 (obesity without diabetes) and REDEFINE-2 (obesity with type 2 diabetes), came out in the new england journal of medicine in 2025 [1][2]. the results were not what the market had priced in, and most of the headlines that followed conflated the press release with the peer-reviewed paper. this post walks what the actual papers say, in plain english, and puts CagriSema next to its closest competitors: semaglutide, tirzepatide, retatrutide, and survodutide.

What REDEFINE-1 actually showed

REDEFINE-1 randomized 3,417 adults with obesity (without type 2 diabetes) to CagriSema 2.4 mg / 2.4 mg, cagrilintide alone, semaglutide alone, or placebo for 68 weeks. The combination produced the largest mean weight loss, beating both single drugs and placebo, with a healthy responder distribution at the ≥5%, ≥10%, ≥15%, and ≥20% thresholds. The incremental benefit over semaglutide alone was meaningful but modest.

REDEFINE-1 enrolled 3,417 adults with obesity or overweight without type 2 diabetes and randomized them across four arms over 68 weeks [1]. one arm got CagriSema at the trial dose of 2.4 milligrams of cagrilintide and 2.4 milligrams of semaglutide, co-formulated in a single weekly injection. the other three arms got cagrilintide alone at 2.4 milligrams, semaglutide alone at 2.4 milligrams, or placebo. all four arms followed a titration schedule -- the dose ramps up gradually over the first roughly 16 weeks to let the gut adjust before reaching the maintenance dose.

The CagriSema arm delivered the largest mean weight loss of the four, exceeding both cagrilintide and semaglutide as standalone drugs. the responder distribution -- the share of participants who hit the ≥5%, ≥10%, ≥15%, and ≥20% weight-loss thresholds -- was healthy at every threshold and clearly above both monotherapies. that is the clinically important number, because mean weight loss can hide a wide spread: the mean is what the middle of the curve does, but a real person is somewhere on the curve, not at the mean.

The cardiometabolic secondaries -- blood pressure, lipids, waist circumference, inflammatory markers -- all moved in the expected direction for the weight lost. the dedicated blood-pressure substudy (Verma 2026) confirmed meaningful systolic and diastolic reductions [3]. gastrointestinal events -- nausea, vomiting, diarrhea, constipation -- were the dominant tolerability issue and were titration-dependent, the familiar GLP-1 class pattern with the amylin arm added on top rather than smoothed out.

Why the press release crashed Novo Nordisk's stock and the paper did not

On December 20, 2024 Novo Nordisk released a topline of about 22.7% mean weight loss at 68 weeks. Analyst expectations had been pricing in 25% or more, so the stock fell sharply. The peer-reviewed Garvey 2025 NEJM paper landed months later with similar headline numbers but full context. The lesson: cite the published paper, never the press release.

On December 20, 2024, Novo Nordisk announced topline REDEFINE-1 results in a press release ahead of any journal publication. the topline number, about 22.7% mean weight loss in the efficacy estimand at 68 weeks, was below where most analysts had set their target. the comparison investors were running in their heads was unfair on multiple axes: tirzepatide SURMOUNT-1 reported about 22.5% at 72 weeks [4] and the retatrutide phase 2 trial reported about 24.2% at 48 weeks [5]. on a quick read, that made CagriSema look like it had not beaten an existing approved drug.

The stock fell sharply -- one of the largest single-day declines for the company in years. several months later the peer-reviewed paper arrived in NEJM and confirmed the topline directionally while giving the full estimand definitions, statistical analysis plan, secondary endpoints, and adverse-event detail. the canonical numbers for any educator or clinical write-up should come from the Garvey 2025 NEJM paper [1], not the press release. this is a general rule that applies to every late-stage trial in this space: a topline press release is a marketing artifact written for shareholders; the peer-reviewed paper is the document the field judges the drug on.

What is the amylin arm actually doing

Cagrilintide acts on the amylin receptor complex, a hybrid receptor made from the calcitonin receptor plus an accessory protein called RAMP. The receptor sits densely in the area postrema, a small brainstem region that senses blood-borne fullness signals. Cagrilintide there reduces meal size, slows gastric emptying, and suppresses postprandial glucagon -- effects mechanistically distinct from GLP-1's action.

The reason CagriSema is not just "more semaglutide" is that cagrilintide targets a different receptor system. amylin is a 37-amino-acid hormone your pancreas releases alongside insulin after a meal. it signals fullness by acting on the amylin receptor complex -- a combination of the calcitonin receptor plus a small accessory protein called RAMP (receptor activity-modifying protein). the complex sits most densely in the area postrema, a small brainstem region with a permeable blood-brain barrier that exists specifically to sense blood-borne fullness signals [6].

Three effects matter. first, cagrilintide reduces meal size by engaging the area postrema satiety circuit. second, it slows gastric emptying through the vagus nerve (the main nerve that connects your brain to your gut and heart). third, it suppresses postprandial glucagon (the hormone that raises blood sugar between meals), improving postprandial glucose. these are complementary to, not overlapping with, semaglutide's GLP-1 actions [7] -- the mechanistic story for why the combination delivers more than either single drug.

The press-release vs paper number, decoded

Trial weight loss is reported under different statistical conventions called estimands. The treatment-policy estimand counts everyone, even those who stopped early. The efficacy estimand counts only those who stayed on drug. The two can differ by 1-3 percentage points. When you read a trial number, look up which estimand it came from before comparing across trials.

One more nuance worth getting right. modern obesity trials report two main weight loss numbers because estimands -- statistical conventions for what question the trial is actually answering -- have become a standard part of FDA labeling. the treatment-policy estimand answers "what happens to everyone we randomized to this drug, regardless of whether they stopped taking it." the efficacy estimand answers "what happens to people who actually stayed on the drug through the trial."

The two numbers differ because some participants stop early and the trial has to decide how to handle them. the efficacy estimand is usually 1 to 3 percentage points higher. cross-trial comparisons go wrong when one trial is quoted under treatment policy and another under efficacy -- always check which one the number came from before claiming one drug beats another.

How CagriSema slots against the rest of the next-gen family

CagriSema, tirzepatide, retatrutide, and survodutide all pair GLP-1 with a second hormonal arm. CagriSema adds amylin (central satiety). Tirzepatide adds GIP (insulin sensitivity). Survodutide adds glucagon (energy expenditure and liver fat). Retatrutide adds both GIP and glucagon. Each second hormone is a different lever on the same outcome, and head-to-head trials between them do not yet exist.

The next-generation obesity drugs are all variations on the same idea: take a GLP-1 agonist and pair it with a second hormonal arm that hits a different lever. tirzepatide adds GIP (glucose-dependent insulinotropic peptide, an incretin that helps fat tissue store fat more efficiently and improves insulin sensitivity). survodutide adds glucagon receptor agonism (which raises energy expenditure and burns liver fat -- the same lever that makes survodutide the standout in liver-disease trials). retatrutide adds both GIP and glucagon to GLP-1, the so-called triple agonist. CagriSema adds amylin (central satiety, gastric-emptying delay, and glucagon suppression).

Mean weight loss in the published phase 3 trials clusters in a tight band. semaglutide STEP-1 reported about 14.9% at 68 weeks [8]. tirzepatide SURMOUNT-1 reported about 22.5% at 72 weeks [4]. CagriSema REDEFINE-1 reported about 22.7% at 68 weeks [1]. retatrutide TRIUMPH-1 topline announced about 28.3% at the 12 milligram dose at 80 weeks (peer-reviewed paper pending as of writing) [9]. survodutide phase 2 reported about 16.6% at 76 weeks. these are different durations and different populations, so the numbers are not strictly comparable. no head-to-head trial exists between any of the four.

Use the projection tool below to put your own starting weight against any of the five. it pulls the mean and the responder distribution from the published trial for each drug, and shows you the pounds-loss and the percentage of trial participants who hit each weight-loss threshold. the GLP-1 comparison tool shows the same drugs in a side-by-side feature table; this tool is the personalized projection.

What CagriSema does not yet have

CagriSema has phase 3 efficacy in obesity and type 2 diabetes but lacks cardiovascular outcomes data, a MASH liver-disease trial, kidney outcomes, long-term durability beyond 68-72 weeks, and head-to-head data against tirzepatide or retatrutide. Semaglutide has cardiovascular outcomes (SELECT, 20% MACE reduction) and MASH approval. Tirzepatide has obesity, T2D, OSA, and MASH approvals. CagriSema has none of those yet.

The CagriSema evidence base is narrower than the broader question implies. the published phase 3 program covers obesity (REDEFINE-1), obesity plus T2D (REDEFINE-2), and an east asian regional confirmatory trial (REDEFINE-5 in japan and taiwan) [10]. none of the major hard endpoints sit in the dataset yet. there is no cardiovascular outcomes trial readout (CVOT -- a trial that asks whether the drug reduces actual heart attacks, strokes, and cardiovascular deaths over years of use). there is no published MASH (metabolic-dysfunction-associated steatohepatitis -- a liver disease that follows fat accumulation and inflammation in the liver) trial. there is no kidney outcomes trial. there is no long-term durability data beyond the 68 to 72 week endpoint.

Semaglutide already has the cardiovascular data: SELECT showed a 20% reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease but without diabetes [11]. it also has a MASH approval. tirzepatide has approvals across obesity, T2D, obstructive sleep apnea (OSA), and MASH. CagriSema has none of those yet. the working assumption is that adding cagrilintide does not undo semaglutide's CV benefit -- reasonable but unproven until REDEFINE-CV reads out.

Realistic interpretation, in three sentences

CagriSema is a strong weekly weight-loss drug with mechanistic novelty (the amylin arm), comparable headline efficacy to tirzepatide, and a peer-reviewed phase 3 evidence base in NEJM. It is not best-in-class because tirzepatide and retatrutide sit in the same band or higher with broader regulatory packages. It is not approved anywhere, so the price, label, and real-world tolerability questions are still ahead.

The honest framing is that CagriSema is competitive, not dominant. the amylin arm is a real mechanistic story with preclinical and clinical support, and the combination is delivering meaningful additional weight loss on top of semaglutide alone. but the field already has tirzepatide approved with a comparable headline number and a broader regulatory package, and retatrutide is sitting on a higher topline figure with a phase 3 readout in the same competitive window. the next-gen GLP-1 field is now a band of similarly effective drugs rather than a single breakaway leader.

For a complete beginner: the semaglutide course walks the GLP-1 backbone every drug on this list is built on. the tirzepatide course, retatrutide course, and survodutide course cover the other second-arm strategies. cagrilintide will get its own dedicated course once REDEFINE-CV or an FDA approval lands.